What is Claimed:

1. A composition comprising citrulline and an Hmg-CoA reductase inhibitor.

2. The composition of claim 1, wherein said citrulline is L-citrulline.

3. The composition of claim 1, wherein said citrulline is a salt of L-citrulline.

4. The composition of claim 1, wherein said citrulline is L-citrulline hydrochloride.

5. The composition of claim 1, wherein the Hmg-CoA reductase inhibitor is pravastatin.

6. The composition of claim 1, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalvastatin.

7. The composition of claim 1, wherein said Hmg-CoA reductase inhibitor enhances nitric oxide production.

8. The composition of claim 1, further comprising a pharmaceutical carrier.

9. The composition of claim 1, wherein the composition is formulated in a form of administration selected from the group consisting of intravenous, buccal, intracoronary, intra-arterial, intrapericardial, intramuscular, tropical, intranasal, rectal, sublingual, oral, subcutaneous, patch and inhalation.

10. A therapeutic composition comprising a therapeutically effective amount of citrulline and an Hmg-CoA reductase inhibitor.

11. The composition of claim 10, wherein said citrulline is L-citrulline.

12. The composition of claim 10, wherein said citrulline is a salt of L-citrulline.

13. The composition of claim 10, wherein said citrulline is L-citrulline hydrochloride.

14. The composition of claim 10, wherein the Hmg-CoA reductase inhibitor is pravastatin.

15. The composition of claim 10, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalvastatin.

16. The composition of claim 10, further comprising a pharmaceutical carrier.

17. The composition of claim 10, wherein the composition is formulated in a form of administration selected from the group consisting of intravenous, buccal, intracoronary, intra-arterial, intrapericardial, intramuscular, tropical, intranasal, rectal, sublingual, oral, subcutaneous, patch and inhalation.

18. A method of treating a subject in need thereof comprising administering a composition comprising citrulline and an Hmg-CoA reductase inhibitor.

19. The method of claim 18, wherein the Hmg-CoA reductase inhibitor enhances nitric oxide synthase activity.

20. The method of claim 18, wherein said citrulline is L-citrulline.

21. The method of claim 18, wherein said citrulline is a salt of L-citrulline.

22. The method of claim 18, wherein said citrulline is L-citrulline hydrochloride.

23. The method of claim 18, wherein the Hmg-CoA reductase inhibitor is pravastatin.

24. The method of claim 18, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalvastatin.

25. The method of claim 18, wherein the composition further comprises a pharmaceutical carrier.

26. A method of stimulating nitric oxide synthase comprising:

administering citrulline and an agonist of nitric oxide synthase.

27. The method of claim 26, wherein said citrulline is in excess to said agonist.

28. The method of claim 26, wherein a therapeutically effective amount of said citrulline is combined with a therapeutically effective amount of an Hmg-CoA reductase inhibitor prior to said administration.

29. The method of claim 29, wherein the Hmg-CoA reductase inhibitor is pravastatin.

30. The method of claim 29, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalvastatin.